Literature DB >> 23963335

Higher risk of recurrent ischemic events in patients with intracranial in-stent restenosis.

Min Jin1, Xian Fu, Yuzhen Wei, Bin Du, Xiao-Tong Xu, Wei-Jian Jiang.   

Abstract

BACKGROUND AND
PURPOSE: Reliable data concerning prognosis of patients with intracranial in-stent restenosis (ISR) is lacking. We prospectively studied long-term outcomes of patients with and without a catheter angiography-verified ISR.
METHODS: Between September 2001 and May 2009, 540 consecutive patients with symptomatic intracranial atherosclerosis received stenting treatment at our institute. Of them, 226 patients with 233 stented arteries had catheter angiography follow-up after stenting and were enrolled into this study. They were clinically followed up until the end of December 2011. Primary end point was ischemic stroke or transient ischemic attack in the territory of the stented artery after the catheter angiography follow-up. ISR was defined as a catheter angiography-verified stenosis of ≥50% within or immediately adjacent (within range of 3 mm) to the implanted stent.
RESULTS: During a mean follow-up of 38.9 months, 27 (11.6%, 27/233) primary end point events were recorded. The risk of primary end point in ISR group was higher compared with non-ISR group (21.1% [12/57] versus 8.5% [15/176]; hazard ratio, 2.94; 95% confidence interval, 1.37-6.30; P=0.005). Multivariable analysis showed that the ISR was an independent risk factor for the primary end point (hazard ratio, 2.79; 95% confidence interval, 1.20-6.49; P=0.017). The median occurrence time of primary end point was 9.9 (interquartile range, 5.0, 21.1) months in ISR group, earlier than that in non-ISR group (26.6 [13.1, 52.9] months; P=0.01).
CONCLUSIONS: In-stent restenosis after stenting of intracranial atherosclerosis is significantly associated with an increased risk and an earlier occurrence of recurrent ischemic events in the territory of the stented intracranial artery.

Entities:  

Keywords:  angioplasty; intracranial arterial disorders; natural history; outcome measures

Mesh:

Year:  2013        PMID: 23963335     DOI: 10.1161/STROKEAHA.113.001824

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  12 in total

1.  Comparison of Drug-Eluting Stent With Bare-Metal Stent in Patients With Symptomatic High-grade Intracranial Atherosclerotic Stenosis: A Randomized Clinical Trial.

Authors:  Baixue Jia; Xuelei Zhang; Ning Ma; Dapeng Mo; Feng Gao; Xuan Sun; Ligang Song; Lian Liu; Yiming Deng; Xiaotong Xu; Yong Zhang; Zengpin Liu; Sheng Guan; Fan Zhang; Bing Li; Hongbo Zheng; Xinfeng Liu; Yajie Liu; Kangning Chen; Jie Shuai; Jieqing Wan; Jun Wang; Xiangqun Shi; Tianxiao Li; Binge Chang; David S Liebeskind; Wengui Yu; Zhongrong Miao
Journal:  JAMA Neurol       Date:  2022-02-01       Impact factor: 18.302

2.  Influence of angioplasty and stenting on intracranial artery stenosis: preliminary results of high-resolution vessel wall imaging evaluation.

Authors:  Chia-Hung Wu; Chih-Ping Chung; Ting-Yi Chen; Kai-Wei Yu; Te-Ming Lin; Wei-An Tai; Chao-Bao Luo; Feng-Chi Chang
Journal:  Eur Radiol       Date:  2022-07-19       Impact factor: 7.034

3.  Incidence and Risk Factors of In-Stent Restenosis for Symptomatic Intracranial Atherosclerotic Stenosis: A Systematic Review and Meta-Analysis.

Authors:  G Peng; Y Zhang; Z Miao
Journal:  AJNR Am J Neuroradiol       Date:  2020-07-30       Impact factor: 3.825

4.  Comparison of 3D T1-SPACE and DSA in evaluation of intracranial in-stent restenosis.

Authors:  Qiuji Shao; Qiang Li; Qiaowei Wu; Tianxiao Li; Li Li; Kaitao Chang
Journal:  Br J Radiol       Date:  2020-12-01       Impact factor: 3.039

Review 5.  Role of stenting for intracranial atherosclerosis in the post-SAMMPRIS era.

Authors:  Dale Ding; Robert M Starke; R Webster Crowley; Kenneth C Liu
Journal:  Biomed Res Int       Date:  2013-11-20       Impact factor: 3.411

6.  Long-Term Risk Factors for Intracranial In-Stent Restenosis From a Multicenter Trial of Stenting for Symptomatic Intracranial Artery Stenosis Registry in China.

Authors:  Xu Guo; Ning Ma; Feng Gao; Da-Peng Mo; Gang Luo; Zhong-Rong Miao
Journal:  Front Neurol       Date:  2021-01-26       Impact factor: 4.003

7.  High-Resolution MR for Follow-Up of Intracranial Steno-Occlusive Disease Treated by Endovascular Treatment.

Authors:  Junjie Wang; Shun Zhang; Jun Lu; Peng Qi; Shen Hu; Ximeng Yang; Kunpeng Chen; Daming Wang
Journal:  Front Neurol       Date:  2021-12-24       Impact factor: 4.003

8.  Spectral Imaging for Intracranial Stents and Stent Lumen.

Authors:  Chi-Lun Weng; Ying-Chi Tseng; David Yen-Ting Chen; Chi-Jen Chen; Hui-Ling Hsu
Journal:  PLoS One       Date:  2016-01-05       Impact factor: 3.240

9.  Tissue Kallikrein Prevents Restenosis After Stenting of Severe Atherosclerotic Stenosis of the Middle Cerebral Artery: A Randomized Controlled Trial.

Authors:  Ruifeng Shi; Renliang Zhang; Fang Yang; Min Lin; Min Li; Ling Liu; Qin Yin; Hang Lin; Yunyun Xiong; Wenhua Liu; Xiaobing Fan; Qiliang Dai; Lizhi Zhou; Wenya Lan; Qinqin Cao; Xin Chen; Gelin Xu; Xinfeng Liu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

10.  Stenting for symptomatic intracranial arterial stenosis in China: 1-year outcome of a multicentre registry study.

Authors:  Ning Ma; Yong Zhang; Jie Shuai; Changchun Jiang; Qiyi Zhu; Kangning Chen; Li Liu; Baomin Li; Xiangqun Shi; Lianbo Gao; Yajie Liu; Feng Wang; Yongli Li; Tieyan Liu; Hongbo Zheng; Dapeng Mo; Feng Gao; Yilong Wang; Yongjun Wang; Lei Feng; Zhongrong Miao
Journal:  Stroke Vasc Neurol       Date:  2018-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.